PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
153.33%
Revenue growth above 1.5x TRVN's 100.00%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
73.30%
Gross profit growth at 75-90% of TRVN's 91.87%. Bill Ackman would demand operational improvements to match competitor gains.
-15.23%
Negative EBIT growth while TRVN is at 40.67%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-15.23%
Negative operating income growth while TRVN is at 40.67%. Joel Greenblatt would press for urgent turnaround measures.
-9.33%
Negative net income growth while TRVN stands at 49.70%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-5.41%
Negative EPS growth while TRVN is at 4.61%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-8.33%
Negative diluted EPS growth while TRVN is at 4.61%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
2.98%
Slight or no buybacks while TRVN is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
2.03%
Slight or no buyback while TRVN is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
-36.10%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-34.66%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
95.84%
10Y OCF/share CAGR above 1.5x TRVN's 51.08%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
71.82%
5Y OCF/share CAGR above 1.5x TRVN's 37.57%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
66.77%
Positive 3Y OCF/share CAGR while TRVN is negative. John Neff might see a big short-term edge in operational efficiency.
96.67%
Net income/share CAGR above 1.5x TRVN's 63.42% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
77.76%
5Y net income/share CAGR 1.25-1.5x TRVN's 64.96%. Bruce Berkowitz would check if a better product mix or cost discipline explains the gap.
53.48%
Positive short-term CAGR while TRVN is negative. John Neff would see a clear advantage in near-term profit trajectory.
61.16%
Below 50% of TRVN's 6176.49%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
-44.17%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
152.11%
Positive short-term equity growth while TRVN is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative near-term dividend growth while TRVN invests at 0.00%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2.25%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-9.40%
We have a declining book value while TRVN shows 35.11%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-0.77%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
8.30%
We increase R&D while TRVN cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
28.80%
We expand SG&A while TRVN cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.